TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10679645
Drug: Octreotide 200
Normalized name: octreotide 200 mcg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 200 microg subcutaneously twice or thrice daily for 1 month
Study: 28493741
Drug: 0.45g/kg alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45g/kg alcohol dose in activational condition
Study: 28493741
Drug: 0.65g/kg alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.65g/kg alcohol dose in activational condition
Study: 28493741
Drug: 0.45g/kg alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45g/kg alcohol dose in inhibitory condition
Study: 28493741
Drug: 0.65g/kg alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.65g/kg alcohol dose in inhibitory condition
Study: 23283838
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) 250 mg
Study: 19633577
Drug: Balsalazide 2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide 2.25 g/day
Study: 11421842
Drug: Bupivacaine 1
Normalized name: bupivacaine 132 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 1 ml kg(‐1)
Study: 11421842
Drug: Bupivacaine 1
Normalized name: bupivacaine 132 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 1 ml kg(‐1) + Tramadol 1.5 mg kg(‐1)
Study: 2695178
Drug: 10 Gy‐Co‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 Gy‐Co‐60 single dose of TBI plus 120 mg/kg of cyclophosphamide over 2 days (Group A)
Study: 2695178
Drug: 12 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 Gy Co‐60 of TBI in 6 fractions (2/day) plus 120 mg/kg of cyclophosphamide over 3 days (Group B)
Study: 38177
Drug: Azathioprine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2.5 mg/kg body weight)
Study: 19855847
Drug: Engerix B
Normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix B hepatitis B vaccine
Study: 17112442
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (9 g)
Study: 7921908
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of glucose in 300 ml of water (G trial)
Study: 7921908
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml of sweetened water (P trial)
Study: 3202370
Drug: Active sustained-release
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active sustained-release theophylline preparation
Study: 3202370
Drug: Placebo sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sustained-release theophylline preparation
Study: 31597020
Drug: Faster increment
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faster increment (30 ml/kg/day)
Study: 31597020
Drug: Slower increment
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slower increment (18 ml/kg/day)
Study: 25728587
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (infliximab and azathioprine)
Study: 19660005
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg single dose
Study: 19660005
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg multiple doses (twice daily for 6 days)
Study: 19660005
Drug: Rivaroxaban (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (various doses: 2.5, 5, 10, 20, 40 mg single dose; 5, 10, 20, 30 mg multiple doses)
Study: 11549430
Drug: Early hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early hormonal therapy with LHRH analogue plus radiotherapy (COMB)
Study: 9820373
Drug: Folate supplementation
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate supplementation (5 mg/d for 6 months)
Study: 8164029
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg i.v. plus ondansetron 8 mg i.v. prechemotherapy plus ondansetron 8 mg orally every 12 hours postchemotherapy for nine doses
Study: 8164029
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg i.v. plus ondansetron 16 mg i.v. prechemotherapy plus placebo orally postchemotherapy
Study: 8164029
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg i.v. plus ondansetron 8 mg prechemotherapy plus ondansetron 8 mg orally postchemotherapy for one dose followed by placebo orally every 12 hours for eight more doses
Study: 2845011
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy (cyclophosphamide, Adriamycin, vincristine alternating with etoposide and cisplatin)
Study: 31994254
Drug: Juul (59
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juul (59 mg nicotine/ml)
Study: 26497643
Drug: Mg-enriched hydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg-enriched hydroxyapatite (Mg-e HA) grafted into the socket for 4 months
Study: 26497643
Drug: Mg-enriched hydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg-enriched hydroxyapatite (Mg-e HA) grafted into the socket for 12 months
Study: 26497643
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of Mg-e HA at 4 months vs 12 months
Study: 24943283
Drug: Good practice
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Good practice treatment intervention (6 hours contact over 24 weeks, group-based)
Study: 8688256
Drug: fentanyl 4
Normalized name: fentanyl 400 MCG Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl 4 micrograms ml‐1 (group F)
Study: 8688256
Drug: 0.05% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% bupivacaine combined with fentanyl 2 micrograms ml‐1 (group BF)
Study: 8250364
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 20 ml bolus of 0.25% bupivacaine followed by a continuous steady rate infusion (10 ml.h‐1)
Study: 8250364
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: Normal saline administered in the same way as Group B
Study: 3030861
Drug: DPTP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPTP vaccine (2 doses)
Study: 3030861
Drug: DPT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPT and IPV (2 doses)
Study: 3030861
Drug: DPT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPT and OPV (2 doses)
Study: 3030861
Drug: DPTP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPTP vaccine (1 year follow-up)
Study: 25367636
Drug: Stress management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress management intervention combining individual cognitive behavioral therapy (CBT) with a brief workplace intervention (N=57)
Study: 15309420
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose loading (75 g glucose in 300 mL water)
Study: 12540321
Drug: Antacids and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids and H2 blockers
Study: 7659477
Drug: Lederle vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lederle vaccine
Study: 7659477
Drug: MPHBL vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPHBL vaccine
Study: 2679953
Drug: Silver sulphadiazine
Normalized name: Silver sulphadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulphadiazine cream (SSD)
Study: 175434
Drug: Metacycline treatment
Normalized name: Metacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metacycline treatment
Study: 29766292
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of extra virgin olive oil (EVOO)
Study: 28618298
Drug: Online Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Behavioral Activation treatment
Study: 28618298
Drug: No stressful
Approvals — FDA: no, EMA: no, PMDA: no
Description: No stressful life event during therapy
Study: 25051124
Drug: CAF-5 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF-5 (5 mg.kg‐1)
Study: 25051124
Drug: CAF-3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF-3 (3 mg.kg‐1)
Study: 25051124
Drug: CAF-1 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF-1 (1 mg.kg‐1)
Study: 22772053
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate (up to 190 mg once a day)
Study: 22772053
Drug: Ivabradine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (up to 7.5 mg twice daily)
Study: 18037672
Drug: Esmolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (1 mg kg(‐1) bolus and infusion of 5‐10 microg kg(‐1) min(‐1))
Study: 16431932
Drug: Blood withdrawal
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood withdrawal (450 ml)
Study: 10881828
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg/kg intravenously)
Study: 8418243
Drug: Oral clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clodronate 1,600 mg/d
Study: 2868413
Drug: Intranasal gonadotropin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal gonadotropin-releasing hormone (1.2 mg per day for 28 days)
Study: 29535135
Drug: Sensor-augmented pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-augmented pump (SAP) insulin delivery
Study: 29535135
Drug: SAP insulin
Normalized name: Bambusa vulgaris sap extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAP insulin delivery
Study: 25037033
Drug: Heptavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent vaccine
Study: 25037033
Drug: Hexavalent and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent and monovalent MenC control vaccines
Study: 20299307
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg daily for 4 days with a gap of 10 days, total 24 courses for 48 weeks)
Study: 20299307
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C tablet (non-chewable, same dosage schedule as azithromycin)
Study: 18716298
Drug: Adalimumab (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (24 mg/m², max 40 mg, subcutaneously every other week for 16 weeks)
Study: 8756373
Drug: Fadrozole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole hydrochloride 0.6 mg three times daily
Study: 8756373
Drug: Fadrozole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole hydrochloride 1 mg twice daily
Study: 8756373
Drug: Fadrozole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole hydrochloride 2 mg twice daily
Study: 8756373
Drug: Fadrozole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole hydrochloride (all doses combined)
Study: 7234694
Drug: Aspirin (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (4.0 g/day)
Study: 30721159
Drug: Body weight‐adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body weight‐adapted CM protocol (0.4 g I/kg dosing factor, TIL adapted to weight)
Study: 30721159
Drug: Fixed CM
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed CM dose (33 g I, 110 mL volume)
Study: 26865200
Drug: Thiazide prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide prescription
Study: 26865200
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent prescription
Study: 22985437
Drug: Normal-PI (NPI:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-PI (NPI: 1.0 g/kg/day)
Study: 22985437
Drug: High-PI (HPI:
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-PI (HPI: 1.2 g/kg/day)
Study: 17719932
Drug: High-dose ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ibuprofen (20 to 30 mg/kg/twice daily, adjusted to a peak serum concentration of 50 to 100 mug/mL)
Study: 17719932
Drug: High-dose ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ibuprofen
Study: 11133596
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intrathecal morphine and sufentanil
Study: 11133596
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine (patient-controlled analgesia)
Study: 9036884
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO) treatment at two atmospheres of pressure for 90 minutes twice a day for a minimum of 10 treatments
Study: 7944639
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of hyaluronan (Hyalgan) in 2 ml of buffered saline, administered weekly for 5 weeks
Study: 7944639
Drug: Hyalgan (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyalgan (treatment group)
Study: 2979277
Drug: Ranitidine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine administration at 18.00 hours
Study: 2979277
Drug: Ranitidine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine administration at 22.00 hours
Study: 2979277
Drug: Ranitidine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine administration with food
Study: 2979277
Drug: Ranitidine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine administration without food
Study: 2979277
Drug: Ranitidine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine administration at both times
Study: 30453344
Drug: Metoclopramide co-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide co-administration
Study: 24043395
Drug: High-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exercise (HIGH; 600 kcal/day)
Study: 22716224
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg (oral capsule)
Study: 17184595
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/day within 24 hours after stroke onset (Group I)
Study: 14529680
Drug: 3-h infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-h infusion of paclitaxel
Study: 14529680
Drug: 6-h infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-h infusion of paclitaxel
Study: 14529680
Drug: 24-h infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h infusion of paclitaxel
Study: 14529680
Drug: 3-h vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-h vs 6-h infusion regimens
Study: 6197766
Drug: Prostacyclin (PGI2)
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (PGI2) at a constant dose of 8 ng kg‐1 min‐1
Study: 26800392
Drug: Riluzole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (50 mg/bid) plus citalopram (40 mg/day)
Study: 26800392
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus citalopram (40 mg/day)
Study: 22426408
Drug: Paclitaxel/carboplatin weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel/carboplatin weekly (60 mg/m2 paclitaxel and AUC 2.7 carboplatin)
Study: 22426408
Drug: Treatment adjustments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment adjustments due to toxicity
Study: 7655109
Drug: Flutrimazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutrimazole 1% cream applied once a day
Study: 7655109
Drug: Bifonazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole 1% cream applied once a day
Study: 31897949
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 2000 IU (50 μg) daily for 12 weeks
Study: 30303923
Drug: Elagolix alone
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix alone (300 mg twice daily)
Study: 30303923
Drug: Elagolix with
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix with 0.5 mg estradiol/0.1 mg norethindrone acetate
Study: 30303923
Drug: Elagolix with
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix with 1.0 mg estradiol/0.5 mg norethindrone acetate
Study: 26975346
Drug: 50,000 U
Normalized name: Decara 50,000 UNT Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 U oral cholecalciferol monthly (Group A)
Study: 26975346
Drug: 50,000 U
Normalized name: Decara 50,000 UNT Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 U oral cholecalciferol bimonthly (Group B)
Study: 24308540
Drug: Garlic (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic (three garlic tablets orally, twice daily for 14 days)
Study: 24308540
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three placebo tablets orally, twice daily for 14 days)
Study: 22137103
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) in postmenopausal women after six months
Study: 16928534
Drug: Instillation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of 120 mL autologous blood into the apical chest drain on the fifth postoperative day, with additional doses on days 7 and 9 if necessary
Study: 16928534
Drug: Instillation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of 120 mL autologous blood
Study: 10960201
Drug: 0.2% ropivacaine/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine/2 microg/mL fentanyl
Study: 1498533
Drug: application-impulse stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: application-impulse stimulation treatment
Study: 6474383
Drug: Verapamil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (4 mg)
Study: 24980612
Drug: Oxytocin nasal
Normalized name: oxytocin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin nasal spray (24 IU B.I.D for participants 16 years and over; 18 IU B.I.D for participants 13-15 years; increased to 40 IU B.I.D for participants 16 years and over; 32 IU B.I.D for participants 13-15 years)
Study: 17350803
Drug: Bread with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread with chamomile infusion sweetened with panela
Study: 10594400
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg o.m. or b.d. for 1 month plus 500 mg clarithromycin (b.d.) and 200 mg furazolidone (b.d.) for 1 week
Study: 10594400
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg (not specified in the intervention but mentioned in results)
Study: 2099197
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg twice daily for seven days
Study: 2099197
Drug: Triple tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple tetracycline 300 mg twice daily for two weeks
Study: 7425389
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Metaproterenol (M) and Theophylline (T)
Study: 30968336
Drug: TA‐ER 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA‐ER 32 mg
Study: 27884686
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 10 mL lidocaine 1% (100 mg) mixed with polyvinyl alcohol particles (355‐500 μm)
Study: 27884686
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 10 mL lidocaine 1% (100 mg) injected after embolization
Study: 19730391
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 or 10 mg/d) + Olmesartan medoxomil (10, 20, or 40 mg/d)
Study: 3688150
Drug: Group occupational
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group occupational therapy
Study: 24076297
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg/day for 5 days (n = 1498)
Study: 20228710
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment for HD
Study: 20228710
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for HD
Study: 12721773
Drug: Ciprofloxacin formulations
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin formulations stored under class IV conditions (40 degrees C, 75% relative humidity)
Study: 12721773
Drug: Diclo 50
Normalized name: Xiclo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclo 50 (Camden) and Dicloflame 50 (Intas) formulations stored under class IV conditions
Study: 12721773
Drug: Ciprofloxacin formulations
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin formulations stored at ambient conditions
Study: 12721773
Drug: Diclo 50
Normalized name: Xiclo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclo 50 (Camden) and Dicloflame 50 (Intas) formulations stored at ambient conditions